Company Profile

Dianomi Therapeutics Inc
Profile last edited on: 10/20/21      CAGE: 862Y0      UEI: EKJHQUGFUJ14

Business Identifier: treatments for inflammatory diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

504 South Rosa Road, Suite 200
Madison, WI 53716
Location: Single
Congr. District: 02
County: Dane

Public Profile

Dianomi Therapeutics Inc, spun out of University of Wisconsin Madison, develops Mineral Coated Microparticle (MCM) technology aimed at improving efficacy and safety of treatments for inflammatory diseases. The company is focused on autoimmune diseases as well as partnering with biotech and pharmaceutical companies for additional applications. The technology mimics natural properties of mineralized tissues (bones, teeth) to preserve and control the release of small and large molecules, mRNA, and nucleic acids. This delivery system has longer sustained deliver capabilities than traditional systems such as polylactic-co-glycol acid (PLGA) or polyethylene glycol (PEG).

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Barry Kurokawa -- CEO, Co-Founder

  Anna Elizabeth Clements -- Sr. Scientist, Co-Founder

  William Murphy -- CSO, Co-Founder

  Martin Ostrowski -- President, Co-Founder